The answer is NO. Here's a patient with neuroblastoma who was treated 18 years ago with GD2.CAR T cells at Baylor @CAGTHouston and still remains in remission. We need more of these stories. researchsquare.com/article/r…

Our work on second primary malignancies after CAR T cells is out @BloodJournal Key take home➡️ 19 T-cell malignancies were reported after CART in FAERS database. However, longer follow-up needed to fully understand the risk #CART #fda #mmsm #lymsm ashpublications.org/blood/ar…

1⃣ Concerns about CART malignant potential have risen after FDA reported CAR TCL cases in patients who received CART. As recipients grow, so do later adverse events not well-captured in trials. #CART #FDA

Hot off the press! Our work on second primary malignancies after commercial CAR T cells is out today in Blood. The FDA released scant information regarding the cases of T cell malignancies after CAR T therapy. Here, we provide more context by diving deep into the FDA Adverse Events Reporting System (FAERS). Read here 👉🏼doi.org/10.1182/blood.202402…

How price per pill of lenalidomide kept on rising in USA 🇺🇸. 22 times the price was raised . From 215 $ in 2005 to 763 $ in 2020. And what all Tricks of the trade played by Celgene to keep the price high and block the entry of generics. And when most of the research was funded by government aided grants. 🤫 This is shocking and insane. I don't know how health economy in USA 🇺🇸 is able to sustain this and will it collapse on one fine day ?? 🤔 And just to compare the same pill is available for close 2 to 3 $ in India 🇮🇳 @JCOOP_ASCO @asco @5_utr @AaronGoodman33 @ManniMD1 @VPrasadMDMPH @Dr_AmerZeidan @dr_yakupergun @DrYukselUrun @NicoleKuderer @gary_lyman

⁦@UNMCHemeOnc⁩ Team @ASH23. Great way to learn about Hematology advances for our patients!

Starting ASH with some fun #ASH23

3) So we did the math. Medicare alone spends ***$5 billion*** on Revlimid each year. US could buy all of it for $20-$100 million (Finland/Canada prices)—saving $5 billion. Every year!! From just this one cancer drug alone!!! But instead, we cut food stamps & kids healthcare. 🔥 Thanks @VincentRK

Our paper is finally in print @BloodJournal! Thanks so much to legend @MarcelaMaus for the thoughtful commentary. ashpublications.org/blood/ar…

Check our new study about the "Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review" @e_JHaem. onlinelibrary.wiley.com/doi/… Always thankful for the mentorship of Dr.@HadidiSamer @HemOncFellows #MedTwitter @USD_SSOM_IM

Yeah … Our paper got accepted! We conducted years of research, spent countless hours to analyze, interpret, & write the manuscript. Editors & reviewers voluntarily spent their time ensuring its quality. Now, we need to pay $4,430 so that you can read it. Isn't that ridiculous?

Excited to share that our review article 'Antigen presentation in cancer-mechanisms and clinical implications for immunotherapy' is out in NRCO! @kailin_yang @GeneCollector

Excited to share that I've been accepted into this year’s ASCO AACR Methods in Cancer Research Workshop! Huge thanks to @VijayaRBhatt1 for his invaluable mentorship. Ready to collaborate and push the boundaries of cancer research! #CancerResearch #ASCOAACRWorkshop 🎉🔬

Our @ASTCT #Aging SIG position paper on #transplant ecosystem in older adults 👇 #geriheme #gerionc led by @SarahAllison10 @ROlinMD @MunshiPashnaMD @DrRichardJLin @Ashley_Rosko1 Andy Artz, et al. sciencedirect.com/science/ar…